Innovative Oncology Drugs Tosk has developed advanced drug candidates like TK-90 and KRAS inhibitors that target challenging cancer pathways and mitigate side effects, signaling opportunities to collaborate with biotech firms or healthcare providers focusing on oncology therapeutics.

Recent Clinical Success Successful Phase 2 trials for TK-90 demonstrate Tosk's capability to deliver promising cancer treatments, which can attract partnerships with clinical research organizations or pharmaceutical distributors aiming to expand innovative cancer care options.

Strategic Advisory Expansion The addition of renowned experts in cancer pharmacology and treatment side effects to Tosk’s advisory boards indicates a focus on cutting-edge research and clinical application, presenting opportunities to engage with specialists and research institutions looking for novel drug solutions.

Substantial Funding and Grants With $3.3 million in combined funding from grants and equity investments, Tosk is well-positioned for scale-up and commercialization efforts, making it a potential partner for investors, contract manufacturing, or early-stage pharmaceutical service providers.

Growing Market Focus Operating in the niche of cancer therapy side effect prevention and gene activity blockade within a high-growth pharmaceutical segment, Tosk offers opportunities for sales channels targeting healthcare providers, research centers, and pharma companies seeking innovative cancer management solutions.